UCB

Industry: Health Care seperator

Sector: Pharmaceuticals & Biotechnology

€ 49.24 <%= Resources.Global.txtUp %>

Updated 08:42:49
ISIN: BE0003739530

Intraday

Market is open (until 16:30) - Delayed 15 min

	26 Mar	UCB SA/NV - Convocation to the Annual General Shareholders' meeting

	22 Feb	UCB SA/NV - Convocation to the Extraordinary General Meeting

	23 Mar	UCB SA/NV: Convocation Annual Shareholders' Meeting

	29 Jun	New data for Vimpat® (lacosamide) showed sustained efficacy for up to 5 years and improved seizure control when added to a broad range of antiepileptic drugs

	18 Jun	Neupro® (rotigotine) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome

	17 Jun	Neupro® (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson's disease

	16 Jun	Cimzia® (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of joint progression in patients with rheumatoid arthritis

	16 Jun	Two-year Cimzia® (certolizumab pegol) data from study showed sustained improvements in household productivity and increased participation in social activities for rheumatoid arthritis patients

	16 Jun	New data from EMBLEM(TM) study shows pipeline drug epratuzumab provided significant efficacy for patients suffering from moderate to severe systemic lupus erythematosus

	10 Jun	UCB strengthens strategic alliance with WILEX

Insufficient flash player version